SNAP25
Synaptosomal-associated protein 25
As of the edition of 20 October 2026, SNAP25 (synaptosomal-associated protein 25, UniProt P60880) has 10 drugs tested at it and 9 companies on the list, 0 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P60880
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 14
- Disease areas
- Nervous system; Bones, joints and muscles; Urinary and reproductive; Pregnancy and women's health; Heart and blood vessels; Skin and connective tissue; Mouth and teeth; Injuries
- Registered trials of its drugs
- 722
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 8 |
| Active | 1 |
| Status not established | 1 |
| Total | 10 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Botulinum toxin type a | Marketed | Phase 4 | none listed |
| Onabotulinumtoxina | Marketed | Phase 4 | Ended 2026 |
| Incobotulinumtoxina | Marketed | Phase 4 | Ended 2022 |
| Abobotulinumtoxina | Marketed | Phase 4 | Ended 2023 |
| Prabotulinumtoxin a | Marketed | Phase 4 | Ends 2031 |
| Daxibotulinumtoxina | Marketed | Phase 4 | Ends 2034 |
| Trenibotulinumtoxine | Marketed | Phase 3 | none listed |
| Letibotulinumtoxina | Marketed | Phase 3 | Ends 2036 |
| RT001 | Active | Phase 3 | none listed |
| YY001 | Status not established | Phase 2 | none listed |
10 of 10 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 3 |
| Engaged | 3 |
| Undetermined | 3 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Hugel | Route B |
| Merz Pharma GmbH & Co. KGaA | Route B |
| Crown | Route B |
The other 6 companies at SNAP25
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at SNAP25, ranked, with the facts behind eachRequest access. Nothing is shown until you do.